ClinicalTrials.gg
RecruitingNCT05821010SYNCHUpdated Aug 27, 2024

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

A Phase 2 interventional study of Lyophilized fecal microbiota transplantation capsules and Placebo capsules in Non Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease and Fecal Microbiota Transplantation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands — 10 open to participants now, 13 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · Netherlands.

Planned enrollment
18th of 32
48 · median 67
Started
2023
with 3 others
Phase 2
10 of 42
1 open now
Primary completion
2026-02
later than 4 of 12 live
Registered
37th of 42
by date
Lead sponsor
4 of 42
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 37th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

10 of the 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Non-alcoholic Fatty Liver Disease with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation capsules to reduce NASH in patients with fibrotic NASH. The main questions to answer are:

  1. Can NASH be treated by altering the gut microbiota using LFMT capsules?
  2. Can NASH be treated using a syntrophic cocktail of synbiotics and will these strains strengthen the effect of FMT?
  3. What are the underlying mechanism by which the aforementioned treatments attenuate NASH?

Participants will be treated with FMT-capsules or placebo, and all participants will receive a cocktail of 3 strains of probiotics and one type of prebiotic.

Read the detailed description

Main objective To investigate the therapeutic potential of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and fructo-oligosaccharides with and without conditioned vegan lyophilized fecal microbiota transplantation (LFMT) capsules to reduce NASH in patients with NASH and NASH-fibrosis.

Secondary objective To investigate the mechanisms of A. soehngenii and pasteurized A. muciniphila combined with B. animalis subsp. lactis and FOS with and without conditioned vegan LFMT capsules in reducing NASH in patients with NASH and NASH-fibrosis.

Study design:

Double-blind randomized placebo-controlled intervention study.

Study population:

Patients between age 18-75 years with biopsy-proven NASH obtained up to 32 weeks before screening based on tandem reading of two expert liver pathologists: SAF Steatosis score ≥1, Activity ≥2, Fibrosis \<4; 50% of participants should at least have NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system.

Intervention:

Recipient participants From day -3 before the first FMT until completion of the study, all recipient participants will receive an oral daily single dose of 5 g FOS. Subsequently, participants will be randomized to lean donor FMT capsules (donors conditioned with WholeFiber) or placebo (blinded design)1.

At baseline (day 0) and at week 8 (day 56) and week 16 (day 112) participants will ingest 21 LFMT or placebo capsules. The study visits will be 8 weeks apart, although a margin of -3 days to +3 days is implemented to take participants schedule and availability into account. In addition, participants will daily take 2 capsules of LFMT or placebo during the whole study period (24 weeks).

The investigators have previously observed that gut microbiota composition in the recipient is affected up to 8-12 weeks after donor FMT1, so this time window ensures a stable donor gut microbiota composition during the study.

During the 24-week intervention period, all participants will take daily doses of 109 A. soehngenii CH-106 cells (dosage based on previous studies including toxicology study)2,3, 1010 B. animalis subsp. lactis BLC1 (a well-studied strain marketed as a probiotic by Sacco SRL) and 3x1010 pasteurized A. muciniphila ATCC BAA-835T cells (dosage based on EFSA approval and obtained from A-Mansia Biotech).

Percutaneous liver biopsies will be performed as a part of screening when participants are theoretically eligible for participation, unless a liver biopsy has been performed in the previous 36 weeks. A tandem-read by two liver pathologists blinded to any other result will determine if patients will be included in the study. At 24 weeks, another liver biopsy will be performed to examine the effect of the FMT, which will also be reviewed by two liver pathologists (again blinded to any other result). The NASH-CRN classification will be assessed on H\&E slides, for steatosis, inflammation and ballooning, and with a Sirius red-stained slide for evaluation of fibrosis. RNA for RNA-sequencing will be isolated.

Differential gene expression will be assessed over time (baseline and 24 weeks) and by treatment allocation (vegan donor FMT versus placebo).

Feces will be collected at baseline, and after week 2, 8, 10, 16, 18, and 24, in order to investigate the changes in gut microbiome. Also, markers of gut barrier function will be assessed.

Blood will be collected at baseline and at 8, 16 and 24 weeks to investigate common liver enzymes, indicators of glycemic control, lipids, and general and more NASH-specific inflammation parameters.

A multiparametric MRI of liver (MRI-PDFF, MR elastography, corrected T1) and of visceral and subcutaneous fat will be performed at baseline and after 24 weeks to estimate visceral and subcutaneous adipose tissue depot volume, hepatic fat content as well as hepatic fibrosis and inflammation.

Continuous glucose measurements will be performed at home using portable devices, during a consecutive period of 1 week (7 days) in the week before baseline, week 1, 9, 17 and 25.

03

Conditions studied

  • Non Alcoholic Steatohepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Fecal Microbiota Transplantation
  • FMT
  • Prebiotics
  • Probiotics
  • Microbiome
  • Intestinal Microbiome
  • Gut Microbiome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven NASH obtained up to 32 weeks before screening: SAF Steatosis score ≥1, Activity ≥2, Fibrosis \<4; 50% of participants should at least have NASH fibrosis stage 1, 2 or 3 according to the NASH CRN fibrosis staging system based on tandem reading of two expert liver pathologists
  • fluency in Dutch or English
  • participants should be able to understand the information and give

Exclusion criteria

Exclusion Criteria:

  • Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year before screening (significant alcohol consumption is defined as more than 2 international units/day for females and more than 3 international units/day for males, on average; 1 international unit contains ±14 grams of alcohol)
  • liver cirrhosis or hepatocellular carcinoma
  • and/or C
  • auto-immune hepatitis
  • Wilson's disease
  • primary sclerosing cholangitis
  • primary biliary cholangitis
  • alpha-1-antitripsine deficiency and hemochromatosis
  • history of liver transplant, current placement on a liver transplant list
  • use of pre-, pro- or synbiotics
  • use of systemic antibiotics 3 month prior to randomization
  • use of tamoxifen, methotrexate or amiodarone
  • prior or planned bariatric surgery
  • active GLP-1 receptor agonist treated diabetes mellitus
  • bleeding disorder
  • (INR) of prothrombin time >1.4 or count \<100 109/L at screening
  • anti-platelet/coagulant therapy use which cannot be temporarily discontinued
  • any major cardiovascular event within 6 months prior to screening (e.g. myocardial infarction, cerebrovascular accident)
  • prolonged compromised immunity (e.g. recent cytotoxic chemotherapy, -infection with a \< 240)
  • active or prior history of invasive (except for curatively treated in situ carcinomas [e.g., cervix] or non-melanoma skin cancer) unless a complete remission was achieved
  • surgery scheduled for the trial duration period, except for minor surgical procedures, in the opinion of the investigator
  • pregnant or nursing women
  • any condition which, in the investigator's opinion, might jeopardize participants' safety or compliance with the protocol
  • participation in another concomitant clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    LFMT-capsules

    LFMT-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.

    Combination Product: Lyophilized fecal microbiota transplantation capsules · Dietary Supplement: A. soehngenii · Dietary Supplement: Pasteurized A. muciniphila · Dietary Supplement: B. animalis subsp. lactis · Dietary Supplement: Fructo-oligosaccharides

  • Placebo comparator
    Placebo

    Placebo-capsules. 3 times bulk, and further continuous administration. This arm is also treated pre- and probiotics.

    Combination Product: Placebo capsules · Dietary Supplement: A. soehngenii · Dietary Supplement: Pasteurized A. muciniphila · Dietary Supplement: B. animalis subsp. lactis · Dietary Supplement: Fructo-oligosaccharides

Interventions

  • Combination productLyophilized fecal microbiota transplantation capsules

    Oral administration (capsule)

  • Combination productPlacebo capsules

    Oral administration (capsule)

  • Dietary supplementA. soehngenii

    Oral administration (capsule)

  • Dietary supplementPasteurized A. muciniphila

    Oral administration (capsule)

  • Dietary supplementB. animalis subsp. lactis

    Oral administration (capsule)

  • Dietary supplementFructooligosaccharideStudies of FructooligosaccharideFructooligosaccharide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration (dissolved in water)

06

What researchers measure

Primary outcomes

  1. Liver histology

    Alteration of liver histology in subjects with NASH and fibrosis stage 0-3, with an alteration defined as change of steatohepatitis by ≥1 SAF-A point, or a change in ≥ 1 stage liver fibrosis.

    Time frame: baseline and after 24 weeks

Secondary outcomes

  1. MRI

    MRI-PDFF, MR elastography, corrected T1

    Time frame: baseline and after 24 weeks

  2. Fibroscan

    CAP and LSM

    Time frame: baseline and after 24 weeks

  3. Liver enzymes (blood)

    alanine amino transferase (ALT), aspartate amino transferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP))

    Time frame: baseline and after 24 weeks; 8 and 16 weeks for safety.

  4. Immunological data

    leukocytes, monocytes, CRP, Il-1(β), Il-6, Il-11, Il-17, Il-32, TNF-α, IFN-γ, other inflammatory markers),

    Time frame: baseline and after 24 weeks

  5. Plasma lipids

    plasma lipids (LDL, HDL, triglycerides, total cholesterol),

    Time frame: baseline and after 24 weeks

  6. Gut metabolites (in blood)

    short chain fatty acids (i.e. propionate, butyrate, acetate), lactate, ethanol,

    Time frame: baseline and after 24 weeks

  7. Glycemic control

    Continuous glucose monitoring (4x 7 consecutive days), HOMA-IR

    Time frame: 5 weeks during study period

  8. albumin, kreatinine, hemoglobin (blood)

    albumin, kreatinine, hemoglobin (blood)

    Time frame: baseline, 8, 16 and 24 weeks

  9. NAFLD NASH related endocrinological and metabolic outcome parameters

    FGF-21, adiponectin, leptin, lipopolysaccharides, estrogen, vitamin B12, folate acid, zonulin, and other metabolomic and lipidomic outcomes.

    Time frame: Baseline and 24 weeks

  10. Microbiome readouts

    microbiome read outs (composition, engraftment, strain tracking) and metabolites, fecal SCFA-composition, and fecal albumine.

    Time frame: baseline and after 24 weeks, and 5 times in between.

  11. Body weight

    Body weight measured without shoes, in kilograms

    Time frame: baseline and after 24 weeks

  12. Height

    Height measured without shoes, in cm

    Time frame: baseline

  13. BMI

    Body mass index, calculated from height and weight kg/m\^2 (kg per meters squared)

    Time frame: baseline and after 24 weeks

  14. Waist circumference

    Measured just cranial of the spina iliaca anterior superior, in cm

    Time frame: baseline and after 24 weeks

  15. Percentage body fat

    Measured with a biometric device, as a percentage.

    Time frame: baseline and after 24 weeks

  16. Demographics and (medical) history

    Sex, age, ethnicity, height, weight, comorbidities (e.g. diabetes), smoking, alcohol intake, medication use, polypharmacy (defined as chronic use of ≥ 5 different medications)

    Time frame: baseline and 24 weeks

  17. Quality of life with CDLQ-NASH

    quality of life with NAFLD/NASH-specific (CDLQ-NAFLD)) questionnaire.

    Time frame: baseline and after 24 weeks

  18. Quality of life with SF36 questionnaire.

    quality of life (general (SF36) questionnaire.

    Time frame: baseline and after 24 weeks

  19. Food diary

    5x 10 days, daily caloric intake, daily fat and sugar consumption

    Time frame: around the visits 0, 8, 16, 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2026, 35 months after the start.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 35 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Apr 20, 2023
StartActual
Mar 17, 2023
Primary completionEst.
Feb 20, 2026
CompletionEst.
Aug 20, 2026
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05821010
Responsible party
Onno Holleboom, MD, PhD (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Apr 20, 2023
Start date
Mar 17, 2023
Primary completion
Feb 20, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Aug 27, 2024

Study contacts

Quinten Augustijn, MD
Contact
q.j.augustijn@amsterdamumc.nl
+31205661267
A.G. Holleboom, MD, PhD
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion